Literature DB >> 8706770

An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers.

A Lönnebo1, A Grahnén, B Jansson, R M Brundin, A Ling-Andersson, S A Eckernäs.   

Abstract

The systemic effects of single and multiple doses of inhaled fluticasone propionate (FP) and budesonide were examined in 24 healthy male volunteers (age range 18-29 years). The study was of an open, placebo-controlled, randomized, three-way crossover design. On each study day, multiple blood samples were taken over a 20 h period after drug administration (after a single dose and after the last of seven doses) and area under the curve (AUC(0-20)) for plasma cortisol and white blood cell (WBC) counts was calculated. RESULTS. The present study shows that multiple dosing with FP 1.0 mg b.i.d. for 3.5 days (seven doses) resulted in a marked cortisol suppression from placebo which, at 55%, was more than double that seen with a single dose (25% suppression). Multiple dosing with budesonide 0.8 mg b.i.d. resulted in a 34% suppression in plasma cortisol compared with a suppression of 26% with a single dose. The increase in systemic activity of FP after multiple dosing is confirmed by both the number of subjects with 0800 hours plasma cortisol values below normal limits and by the changes in WBC and differential counts. CONCLUSION. The results of the present study confirm previous findings with regard to the more marked systemic effect of FP following multiple dosing as compared with a single dose. This increase in systemic effect from single dosing to multiple dosing is significantly greater for FP than for budesonide.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8706770     DOI: 10.1007/BF00195931

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group.

Authors:  N C Barnes; G Marone; G U Di Maria; S Visser; I Utama; S L Payne
Journal:  Eur Respir J       Date:  1993-06       Impact factor: 16.671

2.  An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers.

Authors:  A Grahnén; S A Eckernäs; R M Brundin; A Ling-Andersson
Journal:  Br J Clin Pharmacol       Date:  1994-12       Impact factor: 4.335

3.  Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid.

Authors:  A Ryrfeldt; P Andersson; S Edsbäcker; M Tönnesson; D Davies; R Pauwels
Journal:  Eur J Respir Dis Suppl       Date:  1982

4.  Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction.

Authors:  R Melchor; M F Biddiscombe; V H Mak; M D Short; S G Spiro
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

Review 5.  Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992.

Authors:  P J Barnes; S Pedersen
Journal:  Am Rev Respir Dis       Date:  1993-10

6.  A sensitive radioimmunoassay, incorporating solid-phase extraction, for fluticasone 17-propionate in plasma.

Authors:  B M Bain; G Harrison; K D Jenkins; A J Pateman; E V Shenoy
Journal:  J Pharm Biomed Anal       Date:  1993-07       Impact factor: 3.935

7.  A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group.

Authors:  R Dahl; B Lundback; J L Malo; J A Mazza; M M Nieminen; P Saarelainen; H Barnacle
Journal:  Chest       Date:  1993-11       Impact factor: 9.410

8.  Hypothalamo-pituitary-adrenal axis suppression in asthmatics inhaling high dose corticosteroids.

Authors:  P H Brown; G Blundell; A P Greening; G K Crompton
Journal:  Respir Med       Date:  1991-11       Impact factor: 3.415

9.  Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects.

Authors:  L Borgström; E Bondesson; F Morén; E Trofast; S P Newman
Journal:  Eur Respir J       Date:  1994-01       Impact factor: 16.671

10.  A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects.

Authors:  A Grove; C Allam; L C McFarlane; G McPhate; C M Jackson; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1994-12       Impact factor: 4.335

  10 in total
  13 in total

1.  Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients.

Authors:  D J Clark; B J Lipworth
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

2.  Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children.

Authors:  B J Lipworth; D J Clark; L C McFarlane
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

Review 3.  Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids.

Authors:  B J Lipworth; J R Seckl
Journal:  Thorax       Date:  1997-05       Impact factor: 9.139

Review 4.  Dose-response of inhaled drugs in asthma. An update.

Authors:  D J Clark; B J Lipworth
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

5.  Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease.

Authors:  S D Singh; C Whale; N Houghton; P Daley-Yates; S M Kirby; A A Woodcock
Journal:  Br J Clin Pharmacol       Date:  2003-04       Impact factor: 4.335

6.  An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy.

Authors:  S Krishnaswami; G Hochhaus; H Derendorf
Journal:  AAPS PharmSci       Date:  2000

7.  Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler.

Authors:  L Thorsson; S Edsbäcker; A Källén; C G Löfdahl
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

8.  A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids.

Authors:  B Meibohm; G Hochhaus; H Möllmann; J Barth; M Wagner; M Krieg; R Stöckmann; H Derendorf
Journal:  J Pharmacokinet Biopharm       Date:  1999-04

9.  An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteers.

Authors:  Anna Lönnebo; Anders Grahnén; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2007-03-01       Impact factor: 4.335

Review 10.  Adverse Effects of Nonsystemic Steroids (Inhaled, Intranasal, and Cutaneous): a Review of the Literature and Suggested Monitoring Tool.

Authors:  Ratika Gupta; Luz S Fonacier
Journal:  Curr Allergy Asthma Rep       Date:  2016-06       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.